Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
EDTA: Auxiliary Complexing Reagents01:26

EDTA: Auxiliary Complexing Reagents

EDTA titrations are usually carried out in highly basic conditions, where the fully deprotonated form of EDTA, Y4−, actively complexes with the free metal ions in the solution. Several metal ions precipitate as hydrous oxide (hydroxides, oxides, or oxyhydroxides) under these conditions, lowering the concentration of free metal ions in the solution. For this reason, auxiliary complexing agents or ligands such as ammonia, tartrate, citrate, or triethanolamine are used in EDTA titrations to...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Recombinant DNA01:09

Recombinant DNA

Overview
Recombinant DNA01:09

Recombinant DNA

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Front-of-package nutrition labeling and obesity implications.

American journal of preventive medicine·2011
Same author

Random plasma glucose measurement may improve the diagnostic specificity of highly sensitive troponin in the emergency department.

International journal of cardiology·2011
Same author

Serum concentration of neopterin on admission does not improve the diagnostic performance of highly-sensitive troponin I.

Clinical chemistry and laboratory medicine·2011
Same author

Intermittent hypobaric hypoxia applicability in myocardial infarction prevention and recovery.

Journal of cellular and molecular medicine·2011
Same author

Fibrinogen replacement therapy: a critical review of the literature.

Blood transfusion = Trasfusione del sangue·2011
Same author

Cardiac troponins and physical exercise. It's time to make a point.

Biochemia medica·2011
Same journal

Bridging the Gap in Laboratory Monitoring of Extended Half-Life Factor VIII and IX: Can Thrombin Generation Assays Overcome Assay Discrepancies?

Seminars in thrombosis and hemostasis·2026
Same journal

External Quality Assessment for Low Molecular Weight Heparin Monitoring in the Australasia/Asia-Pacific Region.

Seminars in thrombosis and hemostasis·2026
Same journal

Human evolution: between hemorrhage and thrombosis.

Seminars in thrombosis and hemostasis·2026
Same journal

Full- vs Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Cancer-Associated Thrombosis: A Multicenter Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
Same journal

Too Old for PESI?: Risk Stratification of Octogenarians with Pulmonary Embolism in the Emergency Department.

Seminars in thrombosis and hemostasis·2026
Same journal

Acute Management and Bleeding Outcomes in Pediatric Pulmonary Embolism: A Large Single-Center Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
See all related articles

Related Experiment Video

Updated: Jun 10, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Recombinant factor VIII concentrates.

Massimo Franchini1, Giuseppe Lippi

  • 1Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy. massimo.franchini@azosp.vr.it

Seminars in Thrombosis and Hemostasis
|July 16, 2010
PubMed
Summary
This summary is machine-generated.

Recombinant factor VIII (rFVIII) concentrates have advanced hemophilia A treatment, improving safety by reducing pathogen transmission risks. Current products offer various formulations, with inhibitor development remaining a key management challenge.

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Extracellular Vesicle Tissue Factor Activity Assay
03:53

Extracellular Vesicle Tissue Factor Activity Assay

Published on: December 29, 2023

Related Experiment Videos

Last Updated: Jun 10, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Extracellular Vesicle Tissue Factor Activity Assay
03:53

Extracellular Vesicle Tissue Factor Activity Assay

Published on: December 29, 2023

Area of Science:

  • Hematology
  • Biotechnology
  • Pharmacology

Background:

  • Recombinant factor VIII (rFVIII) concentrates have been pivotal in hemophilia A treatment for two decades.
  • Available rFVIII products are categorized into three generations based on formulation and stabilizers.
  • The introduction of rFVIII has significantly enhanced the safety of hemophilia A therapy.

Purpose of the Study:

  • To review the characteristics of commercially available recombinant factor VIII concentrates.
  • To summarize the clinical hemostatic efficacy and safety data of rFVIII products.
  • To provide an overview of advancements in hemophilia A management.

Main Methods:

  • Literature review of commercially available rFVIII concentrates.
  • Analysis of product characteristics, including stabilizers (albumin, sucrose) and absence of plasma proteins.
  • Synthesis of published data on clinical efficacy and safety profiles.

Main Results:

  • First-generation rFVIII uses albumin; second-generation uses sucrose; third-generation avoids plasma proteins.
  • rFVIII concentrates have markedly improved hemophilia A treatment safety, minimizing blood-borne pathogen risks.
  • Development of FVIII inhibitors remains a significant challenge in hemophilia A management.

Conclusions:

  • Commercially available rFVIII concentrates represent significant therapeutic advancements for hemophilia A.
  • Understanding the distinct characteristics of rFVIII generations is crucial for optimal patient management.
  • Ongoing research and development are essential to address challenges like FVIII inhibitor formation.